Treatment of multiple myeloma with high-dose chemotherapy and peripheral blood stem cell transplantation followed by maintenance therapy with interferon alpha or by sequential maintenance therapy with interferon alpha and dexametazone randomized trial "4w" of Czech Myeloma Group;Léčba mnohočetného myelomu vysokodávkovanou chemoterapií s autologní transplantací periferních kmenových buněk a následující udržovací léčbou interferonem alfa nebo interferonem alfa a dexametazonem randomizovaná

Klinicka Onkologie

Volumn 15, Issue SUPPL., 2002, Pages 21-27

  Hajek R ^a   Krejci M ^a   Scudla V ^a   Bacovsky J ^a   Vytrasova M ^a   Faber, E ^a   Papajik T ^a   Schutzova M ^a   Koza, V ^a   Sumna E ^a   Kuca B ^a   Frankova H ^a   Lehanka, F ^a   Stepankova H ^a   Gumulec, J ^a   Stavarova Y ^a   Rezek, Z ^a   Praskac P ^a   Cahova S ^a   Vranova M ^a   Veprek K ^a   Trason T ^a   Kessler, P ^a   Pozdenova V ^a   Walterova L ^a   Stefanek I ^a   Matuska M ^a   Kralova E ^a   Dastych, M ^a   Heinzova V ^a   Meluzinova I ^a   Tothova E ^a   Stecova N ^a   Novosadova L ^a   Hausdorf, P ^a   Lenickova S ^a   Seifertova N ^a   Bencikova V ^a   Vostrejsova S ^a   Mayer, J ^a   Vorlicek J ^a   Adam, Z ^a   more..

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Autologous tranplantation; Interferon alpha; Myeloma; Randomized trial

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTERMETHOD COMPARISON; LIVER TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0036413512     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Adam Z., Hájek R., Sčudla V. et al.: Therapy of multiple myeloma with high dose melphalan and peripheral blood stem cell (PBSC) support, followed maintenance therapy with interferon alpha monotherapy or sequential maintenance therapy IFN and dexamethasone. Report from ongoing trial 4W of Czech myeloma group. Bone Marrow Transplant. 1998, 21, Supl. 1, abstract 740.
2. Adam Z., Krejčí M., Bačovský J. et al.: Léčba mnohočetného myelomu vysokodávkovanou chemoterapií s transplantací autologních kmenových hemopoetických buněk a následnou udržovací léčbou interferonem alfa nebo interferonem alfa a dexamethasonem. Vnitř. Lék. 1998, 44, 400-408.
3. Adam Z., Pour L, Svobodník A., Ščudla V. et al.: Kvalita života a tolerance udržovací léčby u pacientů s mnohočetným myelomem. Vnitř. Lék. 2002, 3, 216-229.
4. Attal M., Harousseau J. L., Stoppa A. M. et al.: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med. 1996; 335: 91-97.
5. Barlogie B., Jagannath S., Mushi N. et al.: Biology and therapy of multiple myeloma in 1996. Semin. Hematol. 1997; 34: Suppl. 1, 62-67.
6. Barlogie B., Jagannath S., Vesole D. H. et al.: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
7. Bladé et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Brit. J. Haematol. 1998, 102, 1115-1123.
8. Durie B., Salmon, S.: A clinical staging systém for multiple myeloma. Cancer 1975; 36: 842-852.
9. Facon T.: Prognostic factors in low tumour mass asymptomatic multiple myeloma. Amer. J. Hematol. 1995; 48: 71-75.
10. Goldschmidt H., Hegenbert U., Wallmeier, M. et al.: High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann. Oncol. 1997; 8: 243-246.
11. Hájek R., Adam Z., Ščudla V. et al.: Report of the randomized trial "4W" of Czech Myeloma Group: Maintenance therapy with interferon alpha-2b (IFN) monotherapy or sequential maintenance therapy IFN and dexamethasone (DEX) after high dose melphalan and peripheral blood stem cell (PBSC) support in patients with multiple myeloma. J. Clin. Oncol. 1998, 17, abstr. 100.
12. Krejčí M., Hájek R., Ščudla V. et al.: Autologní transplantace periferních hemopoetických buněk a následná udržovací terapie interferonem alfa nebo interferonem alfa a dexamethasonem u nemocných s mnohočetným myelomem - Průběné výsledky randomizované klinické studie 4W České myelomové skupiny. Vnitř. Lék. 2001, 47, Suppl., 40-47.
13. Lenhoff S., Hjorth M., Holmberg E. et al.: Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7-11.
14. Salmon, S. E., Crowley J. J. et al.: Interferon versus interferon plus prednisone as remission maintenance therapy for multiple myeloma: A Southwest Oncology Group Study. J. Clin. Oncol. 1998, 16, 890-896.
15. nd ed. Prentice Hall. London, 686 stran.